Iovance Biotherapeutics Inc has a consensus price target of $20.82, established from looking at the 80 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Truist Securities, and HC Wainwright & Co. on March 14, 2024, March 7, 2024, and March 4, 2024. With an average price target of $25.67 between Piper Sandler, Truist Securities, and HC Wainwright & Co., there's an implied 119.00% upside for Iovance Biotherapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/14/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 62.12% | Piper Sandler | Joseph Catanzaro | $18 → $19 | Maintains | Overweight | Get Alert |
03/07/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 121.84% | Truist Securities | Asthika Goonewardene | $17 → $26 | Maintains | Buy | Get Alert |
03/04/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 173.04% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
03/01/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 113.31% | Wells Fargo | Yanan Zhu | $22 → $25 | Maintains | Overweight | Get Alert |
02/29/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 173.04% | HC Wainwright & Co. | Joseph Pantginis | → $32 | Reiterates | Buy → Buy | Get Alert |
02/29/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 79.18% | Goldman Sachs | Andrea Tan | $19 → $21 | Maintains | Buy | Get Alert |
02/29/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 87.71% | Barclays | Peter Lawson | $18 → $22 | Maintains | Overweight | Get Alert |
02/21/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 62.12% | Goldman Sachs | Andrea Tan | $13 → $19 | Maintains | Buy | Get Alert |
02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 113.31% | JMP Securities | Reni Benjamin | $18 → $25 | Maintains | Market Outperform | Get Alert |
02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 87.71% | Wells Fargo | Yanan Zhu | $17 → $22 | Maintains | Overweight | Get Alert |
02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 62.12% | Goldman Sachs | Andrea Tan | $13 → $19 | Maintains | Buy | Get Alert |
02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 53.58% | Piper Sandler | Joseph Catanzaro | $14 → $18 | Maintains | Overweight | Get Alert |
02/20/2024 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 190.1% | Chardan Capital | Geulah Livshits | $29 → $34 | Maintains | Buy | Get Alert |
12/27/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 138.91% | HC Wainwright & Co. | Joseph Pantginis | $38 → $28 | Maintains | Buy | Get Alert |
12/27/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 45.05% | Truist Securities | Asthika Goonewardene | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
11/20/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 2.39% | Goldman Sachs | Andrea Tan | → $12 | Initiates | → Buy | Get Alert |
11/08/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 138.91% | HC Wainwright & Co. | Joseph Pantginis | $38 → $28 | Maintains | Buy | Get Alert |
09/18/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 53.58% | Barclays | Peter Lawson | $40 → $18 | Maintains | Overweight | Get Alert |
09/15/2023 | IOVA | Buy Now | Iovance Biotherapeutics | $11.72 | 45.05% | Truist Securities | Asthika Goonewardene | → $17 | Reiterates | Buy → Buy | Get Alert |
The latest price target for Iovance Biotherapeutics (NASDAQ: IOVA) was reported by Piper Sandler on March 14, 2024. The analyst firm set a price target for $19.00 expecting IOVA to rise to within 12 months (a possible 62.12% upside). 44 analyst firms have reported ratings in the last year.
The latest analyst rating for Iovance Biotherapeutics (NASDAQ: IOVA) was provided by Piper Sandler, and Iovance Biotherapeutics maintained their overweight rating.
The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.
The last downgrade for Iovance Biotherapeutics Inc happened on December 9, 2022 when Goldman Sachs changed their price target from $20 to $6 for Iovance Biotherapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a maintained with a price target of $18.00 to $19.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $11.72, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.